Fuan Pharmaceutical announced on December 22 that its subsidiary Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. obtained the “Drug Registration Certificate” for trazodone hydrochloride tablets approved and issued by the State Drug Administration. Trazodone hydrochloride tablets are used to treat depression. Obtaining the above drug registration certificate will further enrich the subsidiary's product line and enhance its market competitiveness. However, due to factors such as industry policies and changes in the market environment, there is uncertainty about the production and sales situation of these products and the specific impact on the company's performance.

Fuan Pharmaceutical announced on December 22 that its subsidiary Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. obtained the “Drug Registration Certificate” for trazodone hydrochloride tablets approved and issued by the State Drug Administration. Trazodone hydrochloride tablets are used to treat depression. Obtaining the above drug registration certificate will further enrich the subsidiary's product line and enhance its market competitiveness. However, due to factors such as industry policies and changes in the market environment, there is uncertainty about the production and sales situation of these products and the specific impact on the company's performance.